|Vaccine type||Protein subunit|
| Routes of|
|Part of a series on the|
Vabiotech COVID-19 vaccine is a COVID-19 vaccine candidate developed by the Vaccine and Biological Production Company No. 1 (Vabiotech) in Vietnam.
In May 2020, Vietnam declared that their COVID-19 vaccine was developed after scientists successfully generated the novel coronavirus antigen in the lab. The vaccine has been developed by collaborating scientists at VABIOTECH in Hanoi and the Bristol University, it will be tested further in animals and evaluated for safety and effectiveness before a manufacturing process is embarked on. According to the National Institute of Hygiene and Epidemiology, it will take at least 12–18 months to develop vaccine that can work safely on human.During the testing phase, researchers experimented by injecting the mice in many ways and administering multiple antigen doses, with some mice injected with one or two doses of 3-10 micrograms each. After 10 days, 50 mice were in good health and being closely monitored for immune responses. After gaining positive results with immune response and antibody production, the trial vaccine would be developed into a complete and stable version qualified to be used on humans. The research team would also develop commercial production procedures for mass-production, including up to tens of millions of units.
In October 2020, the vaccine has been tested on 12 rhesus macaques (Macaca mulatta) in an island off the northern Quang Ninh province.The macaques are aged 3–5, weighing more than three kilograms each, and not infected with contagious diseases like tuberculosis or the HIV virus. Before being injected with the vaccine, they had their body temperatures, blood and swab samples taken and were kept separately in cages. They will be tested in two periods. In each period, they will be divided into two groups, with one being vaccinated and the other not. After that, they will be monitored daily on separate islands, before their blood samples are taken for further analysis. The testing will follow a similar model that maybe later performed on humans. The animals will be injected two shots of the vaccine, 18 to 21 days apart. A month after the second shot, researchers will assess the monkeys' immune response to see the difference between the injected group and the non-injected group. The result of these trials will be presented before the health ministry's ethical board within the following four months if experiments show the vaccine does produce effective immunogenicity and provide effective protection against COVID-19. It will be a foundation for the next stage for testing the vaccine on humans.
The COVID-19 pandemic in Vietnam is part of the ongoing global pandemic of coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2. As of 21 December 2021, Vietnam has officially reported 1,571,780 laboratory confirmed cases, 1,160,090 recoveries, and 30,041 deaths, the 4th highest in Southeast Asia after Indonesia, the Philippines, Malaysia; and the 32th highest in the world. Hồ Chí Minh City is the most-affected locale with 496,818 confirmed cases and 19,190 deaths, but the Vietnam Ministry of Health estimated that the real number of cases may be four to five times higher.
This article refers to sports broadcasting contracts in Vietnam. For a list of rights in other countries, see Sports television broadcast contracts.
Thủ Đức is a municipal city (sub-city) under the administration of Ho Chi Minh City, Vietnam.
The following is a timeline of the COVID-19 pandemic in Vietnam.
Nanocovax is a Vietnamese COVID-19 vaccine candidate developed by Nanogen Pharmaceutical Biotechnology JSC. It is a subunit vaccine.
The COVID-19 vaccination in Vietnam is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in response to the ongoing pandemic in the country. Following the approval of the Oxford–AstraZeneca COVID-19 vaccine on 30 January 2021, vaccinations commenced on 8 March 2021, and will continue throughout the year with the goal of vaccinating 80% of the population by June 2022. The Sputnik V was later approved for use on 23 March 2021. The Sinopharm BIBP vaccine was approved for emergency use on 4 June 2021, while Pfizer–BioNTech COVID-19 vaccine, Moderna COVID-19 vaccine and Janssen COVID-19 vaccine were approved on 12 June 2021, 29 June 2021, and 15 July 2021, respectively. Vietnam approved Abdala vaccine from Center for Genetic Engineering and Biotechnology on 18 September 2021, and Covaxin from Bharat Biotech on 10 November 2021.
ARCT-154, also known as VBC-COV19-154 in Vietnam, is a COVID-19 vaccine candidate developed by Arcturus Therapeutics. For its development, Arcturus collaborated with Vinbiocare, a Vietnamese company, for support with clinical trials and manufacturing.
The government of Vietnam has initially responded to the COVID-19 pandemic in the country with preventive measures to curb the spread of the coronavirus disease 2019 in the country. Vietnam has prepared for the epidemic as early as the very first case in China emerged, around mid-December 2019. Vietnam's Prime Minister Nguyễn Xuân Phúc ordered measures to prevent and counter the spread of the disease into Vietnam, as well as to warn Vietnamese citizens to avoid visiting areas with outbreaks. Deputy Minister Đỗ Xuân Tuyên said that Vietnam is considering closing the border with China as a necessary countermeasure.
|Scholia has a profile for Vabiotech COVID-19 vaccine (Q106357127).|